Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionAnti IL-31 mAb
Molecular Target Interleukin-31 (IL-31)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationDermatitis
Indication DetailsTreat atopic dermatitis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today